3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Breast Neoplasms
20
Neoplasms
19
Lung Neoplasms
11
Carcinoma, Non-Small-Cell Lung
8
Colorectal Neoplasms
6
Uterine Cervical Neoplasms
5
Prostatic Neoplasms
5
Pancreatic Neoplasms
5
Melanoma
5
Carcinoma, Hepatocellular
5
Brain Neoplasms
5
Skin Neoplasms
4
Ovarian Neoplasms
4
Myelodysplastic Syndromes
4
Leukemia, Myeloid, Acute
4
Triple Negative Breast Neoplasms
3
Neoplasm Metastasis
3
Myeloproliferative Disorders
3
Kidney Neoplasms
3
Head and Neck Neoplasms
3
Esophageal Neoplasms
3
Endometrial Neoplasms
3
Carcinoma, Renal Cell
3
Uveal Melanoma
2
Recurrence
2
Neoplasm, Residual
2
Lymphoma, Non-Hodgkin
2
Lymphoma, B-Cell
2
Lung Diseases
2
Glioma
2
Interventions
tremelimumab
2
pembrolizumab
2
Nivolumab
2
Carboplatin
2
poly ICLC
1
osimertinib
1
lenvatinib
1
durvalumab
1
cemiplimab
1
balstilimab
1
Vascular Endothelial Growth Factor A
1
Peptides
1
Pemetrexed
1
Paclitaxel
1
Ipilimumab
1
Docetaxel
1
Blood Specimen Collection
1
Antibodies, Bispecific
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Diabetes Mellitus, Insulin-Dependent, 12
×
Blood Specimen Collection
×
90 days
×
Clear all
NCT04253080
2026-05-20
ENZYMELA
Assistance Publique - Hôpitaux de Paris
Phase NA
Completed
127 enrolled